5 results
This protocol is a follow-up of a previously submitted protocol (Evaluation of [18F]AV-1451 kinetic modelling in patients with Alzheimer*s Disease and healthy controls, protocol nr. 2014.519), in which the optimal (simplified) kinetic model for [18F…
The first objective is to evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 µg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.Key Secondary objectiveTo evaluate the superiority of CHF…
Primary objective:To explore the natural time course of specific [18F]AV-1451 binding in patients with subjective cognitive decline after two and four year follow upa. To compare rate of change in [18F]AV-1451 binding according to baseline amyloid…
The primary objective of this study is to evaluate the efficacy of SC administration of CSL312 as prophylaxis to prevent HAE attacks in subjects with HAE.The secondary objectives of the study are:1. To characterize the clinical efficacy of SC CSL312…
The primary objective of the study is to evaluate the long-term safety of SC administration of CSL312 in the prophylactic treatment of subjects with C1-INH HAE.The secondary objectives of this study are to evaluate the long-term efficacy, safety and…